Plasma Concentrations of Estramustine Phosphate and Its Major Metabolites in Patients with Prostatic Carcinoma Treated with Different Doses of Estramustine Phosphate (Estracyt®).

The authors report preliminary results of a study performed on six patients with by advanced, hormone-refractory prostate cancer. These patients were treated by estramustine phosphate (10 mg/kg) and methotrexate (60 mg/mq). Low toxicity allows the use of this therapy in outpatient regimens. Moreover, the high rate of partial responses (five patients) shows the remarkable efficacy of this therapy, even if follow-up and number of patients are not sufficient to reach definitive conclusions.

Download Full-text

Plasma Concentrations after Three Different Doses of Topical Isotretinoin

Skin Pharmacology and Physiology ◽

10.1159/000211288 ◽

1994 ◽

Vol 7 (3) ◽

pp. 140-144 ◽

Cited By ~ 3

Author(s):

D. Santana ◽

H. Bun ◽

J. Joachim ◽

A. Durand ◽

J.P. Reynier

Keyword(s):

Plasma Concentrations ◽

Different Doses

Download Full-text

The Influence of Treatment with Estrogens and Estramustine Phosphate on Platelet Aggregation and Plasma Lipoproteins in Non-Disseminated Prostatic Carcinoma

The Journal of Urology ◽

10.1016/s0022-5347(17)49991-5 ◽

1984 ◽

Vol 132 (5) ◽

pp. 1021-1024 ◽

Cited By ~ 14

Author(s):

Carl-David Agardh ◽

Peter Nilsson-Ehle ◽

Rolf Lundgren ◽

Anders Gustafson

Keyword(s):

Platelet Aggregation ◽

Prostatic Carcinoma ◽

Plasma Lipoproteins ◽

Estramustine Phosphate

Download Full-text

Metabolism of estramustine phosphate (Estracyt ®) in patients with prostatic carcinoma

European Journal of Drug Metabolism and Pharmacokinetics ◽

10.1007/bf03189482 ◽

1981 ◽

Vol 6 (2) ◽

pp. 149-154 ◽

Cited By ~ 30

Author(s):

S. B. Andersson ◽

P. O. Gunnarsson ◽

T. Nilsson ◽

G. Plym Forshell

Keyword(s):

Prostatic Carcinoma ◽

Estramustine Phosphate

Download Full-text

Histochemical and Biochemical Investigation of Advanced Prostatic Carcinoma Treated with Estramustine Phosphate, Estracyt

Scandinavian Journal of Urology and Nephrology ◽

10.3109/00365597309133665 ◽

1973 ◽

Vol 7 (1) ◽

pp. 18-22 ◽

Cited By ~ 15

Author(s):

Torgny Nilsson ◽

Jonas Müntzing

Keyword(s):

Prostatic Carcinoma ◽

Estramustine Phosphate ◽

Biochemical Investigation ◽

Advanced Prostatic Carcinoma

Download Full-text

Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intra-uterine devices

Acta Endocrinologica ◽

10.1530/acta.0.0930380 ◽

1980 ◽

Vol 93 (3) ◽

pp. 380-384 ◽

Cited By ~ 45

Author(s):

C. G. Nilsson ◽

P. Lähteenmäki ◽

D. N. Robertson ◽

T. Luukkainen

Keyword(s):

Plasma Levels ◽

Plasma Concentrations ◽

In Vitro Release ◽

Individual Variations ◽

One Year ◽

Vitro Release ◽

Different Levels ◽

Uniform Plasma ◽

Different Doses

Abstract. An effort was made to achieve different levels of plasma levonorgestrel (13-ethyl-17α-ethynyl-17-hydroxy-gon-4-en-3-one) (Ng) concentrations by the intra-uterine administration of levonorgestrel-releasing intra-uterine devices (IUD). Three different models were designed to release different doses of Ng daily. Sixteen women volunteered for the study and had a Ng IUD inserted post-menstrually. The effect of the IUDs on the ovulatory pattern was studied by measuring plasma concentration of oestradiol and progesterone by radioimmunoassay. Ng plasma concentrations were also measured by radioimmunoassay. In vitro experiments to measure the release of Ng from each type of device were carried out. Although some overlapping of mean plasma levels of Ng occurred during use of the three models of the IUDs, suppression of ovulation was clearly dosedependent. Wide variations in plasma levels of Ng were seen between individuals but quite uniform plasma levels were seen in each subject for up to one year3. IUDs where in vitro release rates were equivalent to each other also resulted in wide individual variations in plasma concentrations of Ng.

Download Full-text